PATIENT ALERT:  Masks are now optional in our VOA offices. If you are immunocompromised or feeling ill, masking is strongly encouraged. Thank you. CLICK HERE for more details​​​​​​.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 21176

USO 21176

LOXO-BTK-20022: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)

 

Disease Types: Leukemia & Lymphoma Research

Eligibility Requirements:

- Confirmed diagnosis of CLL/SLL requiring therapy per iwCLL 2018 criteria

- Previous treatment with at least one line of therapy that may include a covalent Bruton's tyrosine kinase (BTK) inhibitor

- Platelets greater than or equal to (>)50 x 10^9/liter (L), hemoglobin > 8 grams/deciliter (g/dL) and absolute neutrophil count > 1.0 x 10^9/L

- Adequate organ function

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

- Estimated creatinine clearance > 30 milliliters per minute (mL/min)

Available at:

Virginia Oncology Associates